SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Courtesy of Michael Vi/Getty Images
Drug Development
Lilly Gears Up for ‘Unprecedented Year,’ Touts Promising Pipeline
Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.
January 11, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Abbvie Inc.
Business
AbbVie Braves Humira LOE, Remains Confident in Long-Term Growth
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
January 11, 2023
 · 
2 min read
 · 
Tristan Manalac
Erik McGregor/LightRocket via Getty
Business
Despite Slowdown in COVID, Pfizer Promises Growth
Pfizer forecasts stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses.
January 10, 2023
 · 
2 min read
 · 
Tristan Manalac
SKYRIZI is the new option for psoriatic arthritis.
Business
AbbVie, Anima Strike mRNA Deal Worth Up to $582M
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
January 10, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Business
Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition
Italian biopharma Chiesi Farmaceutici SpA announced Sunday it was acquiring rare disease-focused Amryt Pharma in a deal that could reach up to $1.48 billion in value.
January 9, 2023
 · 
2 min read
 · 
Tristan Manalac
Leon Neal/Getty Images
Drug Development
AstraZeneca Buys CinCor in a Deal Worth Up to $1.8B
The pharma titan adds an intriguing blood pressure medication to its line up with a buyout of CinCor.
January 9, 2023
 · 
2 min read
 · 
Tristan Manalac
Maddie Meyer/Getty Images
Business
Moderna Leans into Oncology with CytomX Deal Worth up to $1.2B
Moderna and CytomX ink a cancer partnership.
January 6, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Amgen
Business
Amgen Makes Early $2B Play to Boost ADC Portfolio
In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.
January 6, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
NovoCure Electrifies NSCLC Space with Pivotal Phase III Win
NovoCure’s novel cancer-fighting platform hits the mark in non-small cell lung cancer.
January 5, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
Galmed Touts Strong Phase III NASH Data for Aramchol
Galmed announces positive late-stage results in biopsy-proven NASH patients.
January 5, 2023
 · 
2 min read
 · 
Tristan Manalac
Vera CEO and founder Marshall Fordyce, M.D./courte
Drug Development
Market Appears to Question Competitive Prospects of Vera’s IgAN Therapy
Vera Therapeutics’ stock crashed following the reveal of data from a Phase IIb study of atacicept in IgAN.
January 4, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Amgen
Drug Development
Reanalysis of Key Trial Flags Fresh Safety Concerns for Amgen’s Repatha (Updated)
Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.
January 4, 2023
 · 
3 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
Chemomab Claims Mid-Stage Win in NASH
Chemomab’s experimental antibody shows promise in NASH.
January 3, 2023
 · 
2 min read
 · 
Tristan Manalac
Business
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
December 22, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
Lexicon’s AAK1 Inhibitor Disappoints in Phase II Postherpetic Neuralgia Study
Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
December 22, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More